Mazdutide 10mg. Used to support weight management, appetite control, reduced food cravings, and metabolic health. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDependent on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Mazdutide is a synthetic dual receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1) and glucagon receptors. A distinct receptor combination from the GLP-1/GIP dual agonism, and a meaningful pharmacological differentiation within CSD’s incretin and metabolic peptide range. iLab Pharma’s formulation supplies 10mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution. An important format consideration for a synthetic peptide with documented sensitivity to aqueous degradation at ambient temperature.
The GLP-1 and glucagon receptor co activation profile of Mazdutide produces a complementary but distinct mechanism from other incretin based research compounds. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression at the pancreatic level, gastric emptying delay, and central nervous system satiety signaling. The well established incretin pathway shared with other GLP-1 agonist compounds. Glucagon receptor co activation introduces a second distinct mechanism operating in the opposite direction at the pancreatic level but producing complementary effects in peripheral tissue. It directly stimulates hepatic glucose output regulation, thermogenic energy expenditure through brown adipose tissue activation, and lipolytic activity in white adipose tissue. The combination of GLP-1 mediated insulin secretion and glucagon mediated energy expenditure stimulation produces a dual mechanism metabolic research profile that has generated significant investigation in obesity and metabolic syndrome research contexts.
Mazdutide’s GLP-1/glucagon receptor profile positions it as a distinct research compound from CSD’s other incretin agonist listings. The GLP-2 TZ and GLP-2 TRZ dual agonist listings combine GLP-1 and GIP receptor activity; adding adipose tissue and bone metabolism research dimensions through GIP pathway engagement. The GLP-3 RTA triple agonist adds glucagon receptor activity on top of the GLP-1/GIP foundation. Mazdutide’s GLP-1/glucagon combination without GIP engagement produces a different receptor interaction profile from all three, making it a valuable reference compound in comparative incretin and glucagon pathway research examining the specific contribution of each receptor combination to the overall metabolic response.
iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and iLab Pharma’s Mazdutide meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside GLP-1 and dual incretin agonist compounds in comparative metabolic receptor pathway studies. Browse CSD’s full peptide range for complete sourcing.
Mazdutide, also known as IBI362 or LY3305677, is a long acting synthetic analogue of the naturally occurring hormone oxyntomodulin. It acts as a dual agonist at the glucagon like peptide 1 (GLP-1) receptor and glucagon receptor, combining two metabolic signaling pathways within a single molecule. This product contains 10mg of lyophilized Mazdutide in a single vial.
Mazdutide has been extensively studied in metabolic research involving obesity, body weight regulation, type 2 diabetes, glucose control, appetite signaling, insulin sensitivity, lipid metabolism, liver fat, and broader cardiometabolic function. Human clinical trials have demonstrated significant effects on body weight and glycemic measures, with additional research examining changes in metabolic risk factors.
Mazdutide simultaneously activates GLP-1 and glucagon receptors. GLP-1 receptor signaling is associated with glucose dependent insulin secretion, appetite regulation, reduced energy intake, and delayed gastric emptying. Glucagon receptor activation adds a distinct metabolic pathway associated with hepatic metabolism, lipid oxidation, and energy expenditure. The combination is designed to provide complementary effects on glucose and body weight regulation.
The compounds differ in the receptors they target. Mazdutide activates GLP-1 and glucagon receptors. Tirzepatide activates GIP and GLP-1 receptors, while retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously. Mazdutide therefore combines incretin related GLP-1 activity with glucagon receptor signaling without directly targeting the GIP receptor.
Yes! This batch is HPLC tested to verify Mazdutide identity and content accuracy at 10mg per vial. A certificate of analysis is available.
